文献速递免疫规划

MF59佐剂四价流感疫苗与标准及替代B株MF59佐剂三价流感疫苗在老年人中的免疫原性和安全性比较

Immunogenicity and safety of MF59-adjuvanted quadrivalent influenza vaccine versus standard and alternate B strain MF59-adjuvanted trivalent influenza vaccines in older adults.
PubMed 文献 · Vaccine · 2019-10-18

多中心双盲随机对照试验将≥65岁成人按2:1:1分配至aQIV组(n=889)、aTIV-1组(n=445)或aTIV-2组(n=444),在2017-2018流感季接种。aQIV对同源株的免疫应答非劣效于aTIV,对aTIV所缺B株的免疫原性优效,反应原性和安全性总体相当。

要点

  • aQIV对全部4株的GMT比值95%CI上限均<1.5,SCR差异95%CI上限均<10%,满足非劣效标准。
  • 对aTIV所缺B株,aQIV满足优效标准:B-Yamagata GMT比值0.70、SCR差异-8.81%;B-Victoria GMT比值0.78、SCR差异-8.11%。
  • aQIV与aTIV在65-74岁、75-84岁、≥85岁及高合并症风险评分者中均显示免疫学获益,反应原性总体可比。

核心结论

  • aQIV对同源流感株诱导与已上市aTIV相似的免疫应答,反应原性和安全性特征可比。
  • aQIV对aTIV所缺的额外B株观察到优效免疫原性,提示aQIV在老年人中可能比aTIV提供更广泛的流感保护。

研究设计与样本

  • 多中心、双盲、随机对照试验,2017-2018流感季纳入≥65岁成人,按2:1:1随机接种aQIV(n=889)、aTIV-1(n=445)或aTIV-2(n=444)。
  • 免疫原性采用血凝抑制(HI)试验评估接种前和接种后21天血清样本对同源流感株的抗体应答。

主要发现

  • aQIV对aTIV满足GMT比值和SCR差异的非劣效标准:GMT比值双侧95%CI上限均<1.5(A/H1N1=1.27,A/H3N2=1.09,B-Yamagata=1.08,B-Victoria=1.08)。
  • aQIV对aTIV满足SCR差异的非劣效标准:SCR差异95%CI上限均<10%(A/H1N1=7.76%,A/H3N2=4.96%,B-Yamagata=3.27%,B-Victoria=2.55%)。
  • aQIV对aTIV所缺B株满足优效标准(GMT比值95%CI上限<1且SCR差异95%CI上限<0):B-Yamagata GMT比值=0.70、SCR差异=-8.81%;B-Victoria GMT比值=0.78、SCR差异=-8.11%。
  • aQIV与aTIV均具免疫原性且耐受良好,反应原性特征总体可比。
  • aQIV的免疫学获益在65-74岁、75-84岁、≥85岁年龄亚组及高合并症风险评分者中亦有显示。

关键数值与推荐

  • 非劣效标准:GMT比值95%CI上限<1.5且SCR差异95%CI上限<10%,aQIV对全部4株均满足。
  • 优效标准:GMT比值95%CI上限<1且SCR差异95%CI上限<0,aQIV对aTIV所缺B株满足。
  • GMT比值:A/H1N1=1.27,A/H3N2=1.09,B-Yamagata=1.08,B-Victoria=1.08(均为95%CI上限)。
  • SCR差异:A/H1N1=7.76%,A/H3N2=4.96%,B-Yamagata=3.27%,B-Victoria=2.55%(均为95%CI上限)。
  • 对aTIV所缺B株:B-Yamagata GMT比值=0.70、SCR差异=-8.81%;B-Victoria GMT比值=0.78、SCR差异=-8.11%。

临床怎么用

  • 原文结论认为aQIV对同源株免疫应答与已上市aTIV相似、反应原性和安全性可比,对额外B株免疫原性优效,可能提供更广泛保护。
  • 原文未据此给出具体接种推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Evaluate whether adjuvanted quadrivalent influenza vaccine (aQIV) elicits a noninferior immune response compared with a licensed adjuvanted trivalent influenza vaccine (aTIV-1; Fluad™) and aTIV-2 containing an alternate B strain, examine whether aQIV had immunological superiority for the B strain absent from aTIV comparators, and evaluate reactogenicity and safety among adults ≥65 years. METHODS: In a multicenter, double-blind, randomized controlled trial, adults ≥65 years were randomized 2:1:1 to vaccination with aQIV (n = 889), aTIV-1 (n = 445), or aTIV-2 (n = 444) during the 2017-2018 influenza season. Immunogenicity was assessed by hemagglutination inhibition (HI) assay conducted on serum samples collected before vaccination and 21 days after vaccination for homologous influenza strains. RESULTS: aQIV met non-inferiority criteria for geometric mean titer ratios (GMT ratios) and seroconversion rate (SCR) differences against aTIV. The upper bounds of the 2-sided 95% confidence interval (CI) for GMT ratios were <1.5 for all 4 strains (A/H1N1 = 1.27, A/H3N2 = 1.09, B-Yamagata = 1.08, B-Victoria = 1.08). The upper bounds of the 95% CI of the SCR differences were <10% for all 4 strains (A/H1N1 = 7.76%, A/H3N2 = 4.96%, B-Yamagata = 3.27%, B-Victoria = 2.55%). aQIV also met superiority criteria (upper bound of 95% CI for GMT ratios <1 and SCR differences <0) for B strain absent from aTIV comparators (B-Yamagata GMT ratio = 0.70, SCR difference = -8.81%; B-Victoria GMT ratio = 0.78, SCR difference = -8.11%). aQIV and aTIV vaccines were immunogenic and well-tolerated. The immunological benefit of aQIV was also demonstrated in age subgroups 65-74 years, 75-84 years, and ≥85 years and in those with high comorbidity risk scores. Reactogenicity profiles were generally comparable. CONCLUSION: aQIV induces a similar immune response as the licensed aTIV vaccine against homologous influenza strains and has a comparable reactogenicity and safety profile. Superior immunogenicity against the additional B strain was observed, indicating that aQIV could provide a broader protection than aTIV against influenza in older adults (NCT03314662).

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Essink B, Fierro C, Rosen J, et al. Immunogenicity and safety of MF59-adjuvanted quadrivalent influenza vaccine versus standard and alternate B strain MF59-adjuvanted trivalent influenza vaccines in older adults. Vaccine. 2019. PMID: 31635976. doi:10.1016/j.vaccine.2019.10.021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。